Federated Hermes
BLCM

Federated Hermes’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Federated Hermes’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-12,500
Closed -$2.88M – 2079
2014
Q4 		$2.88M Buy
+12,500
New +$2.68M 0.01% 804

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Federated Hermes's BLCM Position: Q1 2015 in Review

Federated Hermes sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2015, closing a stake of 12,500 shares — an estimated $2.88M sold.

Federated Hermes first reported a position in BLCM in Q4 2014 and held it in 1 quarter. The position peaked at $2.88M in Q4 2014. 71 funds tracked by Wall St. Rank hold BLCM as of Q1 2015.

  • Federated Hermes reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2015 after selling out during the quarter.
  • Federated Hermes sold 12,500 Bellicum Pharmaceuticals, Inc. shares in Q1 2015, an estimated $2.88M.
  • Federated Hermes first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2014 and held it in 1 quarter.
  • Federated Hermes's Bellicum Pharmaceuticals, Inc. position peaked at $2.88M in Q4 2014.
  • 71 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2015.

Based on Federated Hermes's 13F filing for Q1 2015, filed 8 May 2015.